N-(tert-Butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

Catalog No. :
ACRCTS821
CAS No. :
1416775-83-1
Molecular Formula :
C17H26BNO3
Molecular Weight :
303.21

IUPAC Name:N-(tert-butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N-(tert-Butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$207.00Login to see priceInquiryInquiry
1g95%$413.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(tert-Butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
IUPAC NameN-(tert-butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
MDL No.MFCD24039509
Molecular FormulaC17H26BNO3
Molecular Weight303.21
SMILESO=C(NC(C)(C)C)C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1
InChI KeyPMAFOPIZGWGTGD-UHFFFAOYSA-N
SynonymBenzamide, N-(1,1-dimethylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1416775-83-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACRCTS821 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPLCQ651 route compound structure diagram
    ACPLCQ65160469-70-7
  2. Plus
  3. ACEGVT713 route compound structure diagram
    ACEGVT713269409-73-6 In Stock
  4. Then
  5. ACRCTS821 route product structure diagram
    ACRCTS8211416775-83-1
Inquiry

2. ACRCTS821 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACRCTS821 route product structure diagram
    ACRCTS8211416775-83-1
Inquiry

Comments (0)